将新的临床病理特征应用于晚期甲状腺癌的预后评估。
Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.
机构信息
Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
出版信息
Endocr Relat Cancer. 2012 Apr 10;19(2):C19-22. doi: 10.1530/ERC-11-0371. Print 2012 Apr.
Abstract
In the February 2011 issue of Endocrine-Related Cancer, Deandreis et al. reported that increased FDG uptake was prognostic in patients with metastatic thyroid cancer. Fludeoxyglucose-positron emission tomography (FDG-PET) is routinely used in the staging and follow-up of patients with cancer. This study gives further evidence for the role of FDG-PET scanning in metastatic thyroid cancer, especially to identify patients with aggressive disease requiring systemic therapy.
摘要
在 2011 年 2 月的《内分泌相关癌症》杂志上，Deandreis 等人报告说，转移性甲状腺癌患者的 FDG 摄取增加与预后相关。氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）常用于癌症患者的分期和随访。这项研究进一步证明了 FDG-PET 扫描在转移性甲状腺癌中的作用，特别是用于识别需要全身治疗的侵袭性疾病患者。
相似文献
1
Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.
Endocr Relat Cancer. 2012 Apr 10;19(2):C19-22. doi: 10.1530/ERC-11-0371. Print 2012 Apr.
2
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Endocr Relat Cancer. 2011 Jan 13;18(1):159-69. doi: 10.1677/ERC-10-0233. Print 2011 Feb.
3
PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Endocr Pract. 2019 Aug;25(8):787-793. doi: 10.4158/EP-2018-0607. Epub 2019 Apr 23.
4
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
J Clin Endocrinol Metab. 2006 Feb;91(2):498-505. doi: 10.1210/jc.2005-1534. Epub 2005 Nov 22.
5
Positron emission tomography of the thyroid, with an emphasis on thyroid cancer.
Nucl Med Commun. 2001 May;22(5):485-92. doi: 10.1097/00006231-200105000-00004.
6
Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Eur J Endocrinol. 2015 Sep;173(3):R115-30. doi: 10.1530/EJE-15-0066. Epub 2015 May 6.
7
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Thyroid. 2001 Dec;11(12):1169-75. doi: 10.1089/10507250152741028.
8
The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer.
AJNR Am J Neuroradiol. 2009 Aug;30(7):1431-4. doi: 10.3174/ajnr.A1559. Epub 2009 Apr 2.
9
The value of positron emission tomography (PET) in the management of patients with thyroid cancer.
Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1047-59. doi: 10.1016/j.beem.2008.10.001.
10
Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
J Formos Med Assoc. 2002 Jul;101(7):459-67.
引用本文的文献
1
Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.
J Endocrinol Invest. 2014 Nov;37(11):1099-108. doi: 10.1007/s40618-014-0177-3. Epub 2014 Oct 5.
本文引用的文献
1
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
2
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Endocr Relat Cancer. 2011 Jan 13;18(1):159-69. doi: 10.1677/ERC-10-0233. Print 2011 Feb.
3
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
4
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Clin Cancer Res. 2010 Nov 1;16(21):5260-8. doi: 10.1158/1078-0432.CCR-10-0994. Epub 2010 Sep 16.
5
Inhibition of mutated, activated BRAF in metastatic melanoma.
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
6
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.
Clin Cancer Res. 2009 Jan 15;15(2):485-91. doi: 10.1158/1078-0432.CCR-08-0933.
7
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.
8
Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Cancer. 2008 Jul 1;113(1):48-56. doi: 10.1002/cncr.23515.
9
Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone.
J Pathol. 2008 Jun;215(2):145-54. doi: 10.1002/path.2342.
10
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.
J Clin Endocrinol Metab. 2007 Sep;92(9):3511-6. doi: 10.1210/jc.2007-0594. Epub 2007 May 29.
Zotero 插件